Hagop Kantarjian
UT MD Anderson Cancer Center · MD Anderson Cancer Center, Houston, Texas · M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
12
all conditions, ClinicalTrials.gov
NIH grants tied to them
5
NIH RePORTER
Trial papers
726
PubMed author-name match
Trials
Studies that name Hagop Kantarjian as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:30 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01649622 · Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)M.D. Anderson Cancer Center · withdrawn · Leukemia, Lymphoma · principal investigator
- Ph2NCT01466179 · Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)Amgen Research (Munich) GmbH · completed · Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT01272245 · Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph1NCT01139151 · 4'-Thio-araC (Thiarabine) in Advanced Hematologic MalignanciesM.D. Anderson Cancer Center · completed · Leukemia · study chair
- Ph2NCT01134575 · CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)M.D. Anderson Cancer Center · completed · Acute Lymphoblastic Leukemia · study chair
- Ph2/Ph3NCT00952588 · Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) PatientsAstraZeneca · completed · Acute Myeloid Leukemia · principal investigator
- Ph1NCT00926731 · Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)AstraZeneca · completed · Acute Myeloid Leukemia · principal investigator
- Ph2NCT00422032 · 2 Arm Study of Clofarabine IV in MDS PatientsM.D. Anderson Cancer Center · completed · Myelodysplastic Syndrome, Leukemia · principal investigator
- Ph2NCT00414310 · Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)M.D. Anderson Cancer Center · completed · Myelodysplastic Syndrome, Acute Myelogenous Leukemia · principal investigator
- Ph1NCT00352677 · Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic LeukemiaCytRx · completed · Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia · principal investigator
- Ph2NCT00299156 · Oral Clofarabine Study in Patients With Myelodysplastic SyndromeM.D. Anderson Cancer Center · completed · Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia · principal investigator
- Ph2NCT00113321 · Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine FailureM.D. Anderson Cancer Center · terminated · Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Career Enhancement ProgramP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2003 to 2019 · $69,630 awarded in 2019Same name and institution; not confirmed by an ID
- New Approaches to the Biology and Treatment of Myelodysplastic Syndromes (MDS)P01CA108631 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2008 to 2009 · $1,981,971 awarded in 2009Same name and institution; not confirmed by an ID
- EARLY THERAPEUTICS DEVELOPMENT WITH PHASE 2 EMPHASIS-261017003N01CA017003 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2004 to 2005Same name and institution; not confirmed by an ID
- COMBINED MODALITY THERAPY TO SUPPRESS PHILADELPHIA CHROMOSOME CELLS IN CMLP01CA049639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 1996 to 2000 · $79,323 awarded in 2000Same name and institution; not confirmed by an ID
- CLIN. AND LAB. INVESTIGATIONS OF NEW AGENTS IN LEUKEMIAR55CA056887 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 1992 · $100,000 awarded in 1992Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:30 UTC. The ranking covers the 200 most relevant of 726 PubMed records, and a shared surname and initials can bring in a namesake. All 726 on PubMed
- Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.N Engl J Med · 20032,747 citationsRCR 51.4
- 2,731 citationsRCR 52.7
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.N Engl J Med · 20171,774 citationsRCR 54.7
- A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.N Engl J Med · 20121,769 citationsRCR 44.2
- Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.N Engl J Med · 20101,328 citationsRCR 30.4
- 1,254 citationsRCR 40.6
- 1,249 citationsRCR 38.4
- Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.N Engl J Med · 20101,247 citationsRCR 28.0
- 1,127 citationsRCR 36.3
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.Lancet Oncol · 20151,054 citationsRCR 30.0